Institut Jules Bordet, 121 Boulevard de Waterloo, Brussels, Belgium.
Curr Opin Oncol. 2010 Sep;22(5):513-20. doi: 10.1097/CCO.0b013e32833ae99c.
Epithelial ovarian cancer (EOC) is a prevalent gynecologic malignancy whose prognosis in most cases remains poor despite advances in therapy. In this article, we critically review the available clinical evidence for the choice of first-line chemotherapy in EOC and discuss promising therapeutic strategies.
In the last 25 years, first-line chemotherapy regimens and the indication of systemic treatment for early-stage disease have been better established. Significant progress has been made in the treatment of advanced EOC with the optimization of the carboplatin plus paclitaxel regimen and the use of intraperitoneal chemotherapy for selected patients. Targeted therapies may be approved for EOC in the near future and this would bring more specific treatments and improve outcomes for patients. Validated biomolecular signatures to better define prognosis and to predict response to therapeutic agents are still lacking.
The standard first-line chemotherapy in EOC is based on the doublet carboplatin plus paclitaxel. It may be possible to improve the efficacy of treatment by means of a more intensive dose-dense regimen or by the intraperitoneal delivery of chemotherapy. Significant improvements in the treatment of EOC are expected from the development of antiangiogenic and other targeted agents and from better patient selection.
上皮性卵巢癌（EOC）是一种常见的妇科恶性肿瘤，尽管治疗方法有所进步，但大多数情况下预后仍较差。本文批判性地回顾了 EOC 一线化疗选择的现有临床证据，并讨论了有前途的治疗策略。
在过去的 25 年中，一线化疗方案和早期疾病的全身治疗指征得到了更好的确定。通过优化卡铂联合紫杉醇方案以及为选定患者使用腹腔内化疗，在治疗晚期 EOC 方面取得了重大进展。针对 EOC 的靶向治疗药物可能在不久的将来获得批准，这将为患者带来更具针对性的治疗方法并改善治疗效果。目前仍缺乏能够更好地定义预后和预测治疗药物反应的经过验证的生物分子标志物。
EOC 的标准一线化疗方案基于卡铂联合紫杉醇的双联方案。通过更密集的剂量密集方案或腹腔内化疗给药，可能提高治疗效果。抗血管生成和其他靶向药物的开发以及更好的患者选择有望显著改善 EOC 的治疗效果。
